在IgA病中最先进的治疗方法
Mohit Mathur1, Manisha Sahay2, Brian J G Pereira1
1Visterra, Inc., Waltham, MA, USA.
Indian journal of nephrology
|October 7, 2024
概括
免疫球蛋白A脏病 (IgAN) 是一种常见的脏疾病. 针对其原因的新疗法正在出现,为患有IGAN的患者提供了超越支持性护理的希望.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 全球范围内,免疫球蛋白-A脏病 (IgAN) 是导致原发性淋巴结膜炎的首要原因.
- 很大比例的Igan患者会发展到末期病 (ESKD).
- 增加的银河糖缺乏IgA1 (Gd-IgA1) 驱动免疫复合物的沉积和IgAN中的损伤.
研究的目的:
- 审查目前对IGAN病理学和治疗景观的理解.
- 突出针对特定IgAN致病机制的新兴治疗方法.
- 讨论 IgAN.护理的不断变化的标准.
主要方法:
- 关于IgAN病原和临床试验的文献综述.
- 分析当前和研究中的治疗策略.
- 讨论最近的监管进步,包括替代终点.
主要成果:
- 使用RAS抑制剂和SGLT2抑制剂的支持性护理是当前的主要支柱.
- 有针对性的释放布德索尼德和斯帕森坦获得了加速批准.
- 研究中的疗法针对Gd-IgA1的产生 (APRIL/BAFF抑制剂) 和补充途径.
结论:
- 针对IGAN的治疗场景正在迅速发展,新的向治疗方法正在出现.
- 需要个性化医疗方法来解决各种IGAN病理.
- 随着新疗法的出现,更新的治疗指南和护理标准至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Acute Kidney Injury IV: Diagnostic Studies and Prevention
8
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
8
Chronic Kidney Disease III: Interprofessional Care
2
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
2
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
Nephrotic Syndrome III : Nursing Management
2
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
2
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117


